- Dom Nov 02, 2014 12:55 am
#437504
Peeeero, Japón permite la comercializacion o aplicación de estos tratamientos bastante antes, así que eso de los 39 meses no se aplica. Una vez obtenidos unos resultados provisionales prometedores, puede ser puesto ya en marcha. ¿Por que crees que estamos hablando tanto de Asia? Además, ya cuentan con las instalaciones de la compañía sisheido para llevarlo a cabo.
Esos porcentajes hay que tomarlos con cuidado, porque son de la fase 1, relacionada con la SEGURIDAD del producto, por eso se emplean dosis reducidas, para comprobar su efecto en el organismo y descubrir si hay complicaciones.
Pepejorileto, en el foro baldtruth habían sacado el mismo argumento que tu sobre los "39 meses" y se ha confirmado que no será asi.
Por cierto, esto es en una entrevista con David Hall de replicel:
“Having this many trials is pretty impressive for a small company,” Hall says. “Our model has always been to develop products, demonstrate efficacy and then license to large pharma or cosmetics firms who can do the final commercialization. We want to be the research and development engine that creates revenues from licences and royalties. In fact, Shiseido Company of Japan has already partnered with us on our pattern baldness product. They acquired an exclusive geographic license for Asia.”
"RepliCel’s current pipeline includes trials for tendinosis, pattern baldness and treatments for aging and sun-damaged skin in various stages of development. Hall estimates that data from the tendon and dermal programs will be available to support licensing discussions by 2015, and pattern baldness in 2016."
"Beyond its clinical trials, the success of RepliCel’s products will be put in the hands of licensing partners which have the infrastructure to support commercialization, says Mark Landy, director of research for senior medical technology and regenerative medicine analyst for Summer Street Research in Boston. The good news is that the industry is not having to wait too long for the clinical trials to get proof of concept. “Having data coming in 2015 and 2016 enables the company to accelerate licensing.”"
"With results from clinical trials on the horizon, Hall is confident things are moving forward as they should. “We’ve been quietly building the fundamentals of this business – forging deals with major players, building up a diversified portfolio and strengthening our management team. Every step we take is incrementally adding value to the shareholders and furthering therapies for patients.”"
Tratamientos en uso:
-Minoxidil 5% con ácido azelaico al 5% y mas cosillas
-Finasteride 1mg diario